Cancer detection that's as determined as you are.

While acute lymphoblastic leukemia (ALL) can be aggressive, it is also treatable1—and treatments for ALL have come a long way in recent years. But to make the most of today’s therapies, your doctor needs advanced tools that can detect even the smallest traces of disease. This information can be critical to making important decisions about your care.2-7

When it comes to treating ALL, your doctor’s ability to detect and monitor these traces of disease may be important for making timely and informed decisions about your treatment plan.2-7

MRD testing helps you and your doctor assess your response to treatment, measure your disease over time, and potentially detect early signs of returning cancer by assessing low levels of disease other tests may miss.2-7

Medicare and other major insurance providers cover clonoSEQ testing performed on blood and bone marrow samples from patients with multiple myeloma, DLBCL, CLL or ALL at multiple time points throughout treatment.

Adaptive Assist™ is our patient support program that’s tailored to your individual needs.


  1. Referenced with permission from the NCCN Guidelines for Patients® for Acute Lymphoblastic Leukemia, 2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  1. Short N, et al. Blood Adv. 2022;6(13):4006-4014. 
  2. Liang E, et al. Blood Adv. 2023;7(14):3395-3402. 
  3. Pulsipher M, et al. Blood Cancer Discov. 2022;3(1):66-81. 
  4. Logan A, et al. Biol Blood Marrow Transplant. 2014;20(9):1307-1313.
  5. Muffly L, et al. Blood Adv. 2021;5(16):3147-3151.